Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T

Tempest Therapeutics (TPST) announced a development collaboration with Senlang Biotechnology focused on advancing TPST-4003, a next-generation in vivo CAR-T therapeutic candidate. The program combines proprietary CD7-targeted mRNA/LNP delivery technology with a dual-target CD19/BCMA CAR construct, representing a novel approach to cell therapy design that aims to achieve broader B-cell lineage depletion and immune system reset.

The collaboration establishes a first-in-human investigator-initiated trial expected to enroll approximately 10 patients with neurological autoimmune diseases, with initial focus on myasthenia gravis and multiple sclerosis. First patient dosing is projected for Q4 2026, providing a near-term clinical milestone for TPST investors. This timeline positions the company within typical early-stage biotech development windows and offers a catalyst for data disclosure.

The dual-indication strategy—targeting both autoimmune and oncology applications—expands the potential addressable market for TPST-4003, though early-stage trial data carries inherent scientific and regulatory uncertainty. The partnership with Senlang, described as having established CD7-targeted CAR-T expertise, may de-risk execution but does not guarantee efficacy or safety outcomes in human subjects.

Sector implication: This announcement reflects continued investor appetite for next-generation cell therapy approaches within biotechnology. The mRNA/LNP platform integration and dual-mechanism design represent incremental innovation in immunotherapy, supporting moderate positive sentiment in specialty therapeutics. Biotech valuations remain sensitive to clinical trial outcomes and regulatory pathway clarity.